Literature DB >> 28221254

LONG-TERM REMISSION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH AS-NEEDED ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.

Ilkay Kilic Muftuoglu1, Mostafa Alam, Qi Sheng You, Raouf Gaber, Hema L Ramkumar, Nadia Mendoza, Amit Meshi, William R Freeman.   

Abstract

PURPOSE: To determine the presenting characteristics of patients with neovascular age-related macular degeneration with long-term remission (LTR), which was defined as the absence of intraretinal/subretinal fluid, or hemorrhage, and absence of leakage on fluorescein angiography for longer than 6 months while on as-needed antivascular endothelial growth factor treatment.
METHODS: The presenting characteristics of patients with LTR were compared with a control group including 32 eyes of 28 age-, gender-, and ethnicity-matched patients who did not achieve LTR.
RESULTS: Seventy-four percent of patients in the LTR group had Type 1 choroidal neovascular membrane and 18.5% had retinal angiomatous proliferation. In the control group, 28 eyes had Type 1 choroidal neovascular membrane (87.5%), and none of the patients had retinal angiomatous proliferation; overall, there was a significant difference in lesion types between the 2 groups (P = 0.036). Eyes with LTR at presentation had significantly thinner subfoveal choroidal thickness (147 vs. 178 μm, P = 0.04). There was more intraretinal fluid and less subretinal fluid at the presentation in the remission group (59.3% intraretinal fluid and 11.1% subretinal fluid) compared with the control group (28.1% intraretinal fluid and 34.4% subretinal fluid, P = 0.03).
CONCLUSION: The presence of retinal angiomatous proliferation, thinner choroidal thickness, more intraretinal fluid, and less subretinal fluid at presentation were associated with LTR in patients receiving as-needed treatment for age-related macular degeneration.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28221254      PMCID: PMC5561535          DOI: 10.1097/IAE.0000000000001572

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  20 in total

1.  Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study.

Authors:  Yoshimasa Kuroda; Kenji Yamashiro; Masahiro Miyake; Munemitsu Yoshikawa; Hideo Nakanishi; Akio Oishi; Hiroshi Tamura; Sotaro Ooto; Akitaka Tsujikawa; Nagahisa Yoshimura
Journal:  Ophthalmology       Date:  2015-08-11       Impact factor: 12.079

Review 2.  Age-related macular degeneration.

Authors:  Laurence S Lim; Paul Mitchell; Johanna M Seddon; Frank G Holz; Tien Y Wong
Journal:  Lancet       Date:  2012-05-05       Impact factor: 79.321

3.  An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris.

Authors:  Magali Saint-Geniez; Tomoki Kurihara; Eiichi Sekiyama; Angel E Maldonado; Patricia A D'Amore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

4.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  Anti-VEGF-refractory exudative age-related macular degeneration: differential response according to features on optical coherence tomography.

Authors:  Joo Young Shin; Se Joon Woo; Jeeyun Ahn; Kyu Hyung Park
Journal:  Korean J Ophthalmol       Date:  2013-11-15

6.  One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration.

Authors:  Cheryl A Arcinue; Feiyan Ma; Giulio Barteselli; Lucie Sharpsten; Maria Laura Gomez; William R Freeman
Journal:  Am J Ophthalmol       Date:  2014-11-18       Impact factor: 5.258

7.  Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.

Authors:  Juan E Grunwald; Ebenezer Daniel; Jiayan Huang; Gui-Shuang Ying; Maureen G Maguire; Cynthia A Toth; Glenn J Jaffe; Stuart L Fine; Barbara Blodi; Michael L Klein; Alison A Martin; Stephanie A Hagstrom; Daniel F Martin
Journal:  Ophthalmology       Date:  2013-09-29       Impact factor: 12.079

Review 8.  Choroidal neovascularization in pathological myopia.

Authors:  Kumari Neelam; Chiu Ming Gemmy Cheung; Kyoko Ohno-Matsui; Timothy Y Y Lai; Tien Y Wong
Journal:  Prog Retin Eye Res       Date:  2012-04-28       Impact factor: 21.198

9.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Authors:  Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2012-10-17       Impact factor: 12.079

Review 10.  Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010.

Authors:  Rupert R A Bourne; Jost B Jonas; Seth R Flaxman; Jill Keeffe; Janet Leasher; Kovin Naidoo; Maurizio B Parodi; Konrad Pesudovs; Holly Price; Richard A White; Tien Y Wong; Serge Resnikoff; Hugh R Taylor
Journal:  Br J Ophthalmol       Date:  2014-03-24       Impact factor: 4.638

View more
  7 in total

1.  Durability of every-8-week aflibercept maintenance therapy in treatment-experienced neovascular age-related macular degeneration.

Authors:  Kunny C Dans; Sarah R Freeman; Tiezhu Lin; Amit Meshi; Sergio Olivas; Lingyun Cheng; Manuel J Amador-Patarroyo; William R Freeman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-02-26       Impact factor: 3.117

2.  Reply.

Authors:  Ilkay K Muftuoglu; Mostafa Alam; Qi Sheng You; Raouf Gaber; Hema L Ramkumar; Nadia Mendoza; Amit Meshi; William R Freeman
Journal:  Retina       Date:  2017-09       Impact factor: 4.256

3.  The fate of eyes with wet AMD beyond 4 years of anti-VEGF therapy.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-05-07       Impact factor: 3.117

4.  Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial.

Authors:  Drew Scoles; Gui-Shuang Ying; Wei Pan; Peiying Hua; Juan E Grunwald; Ebenezer Daniel; Glenn J Jaffe; Cynthia A Toth; Daniel F Martin; Maureen G Maguire
Journal:  JAMA Ophthalmol       Date:  2020-03-01       Impact factor: 7.389

5.  Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol.

Authors:  Tiezhu Lin; Kunny C Dans; Ilkay Kilic Muftuoglu; Amit Meshi; Manuel J Amador-Patarroyo; Lingyun Cheng; William R Freeman
Journal:  Br J Ophthalmol       Date:  2019-07-13       Impact factor: 4.638

6.  Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission.

Authors:  Han Joo Cho; Young Joon Jeon; Wontae Yoon; Jihyun Yoon; Jaemin Kim; Jong Woo Kim
Journal:  Sci Rep       Date:  2022-09-19       Impact factor: 4.996

7.  Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis.

Authors:  Lu Ye; Zhao Jiaqi; Wang Jianchao; Feng Zhaohui; Yao Liang; Zhang Xiaohui
Journal:  Ther Adv Chronic Dis       Date:  2020-09-04       Impact factor: 5.091

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.